Astellas rejoins the autoimmune antibody craze with Pandion partnership
Over a year ago, Astellas CEO Kenji Yasukawa announced a large R&D restructure: 600 cut jobs, multiple research subsidiaries shut down, and a rejiggered early pipeline approach centered on so-called “focus areas.” Each focus area was detailed briefly in a report they released, along with how they’d reach the therapy.
But one sub-focus area looked different. Rather than list the features of their technology, the space below auto-antibodies (a form of autoimmune disorder) said simply “development of new platform.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
